Bank of New York Mellon Corp grew its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) by 2.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 759,600 shares of the medical instruments supplier’s stock after purchasing an additional 16,089 shares during the period. Bank of New York Mellon Corp owned approximately 1.24% of OraSure Technologies worth $12,510,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new stake in shares of OraSure Technologies during the second quarter worth $122,000. Engineers Gate Manager LP purchased a new stake in shares of OraSure Technologies during the second quarter worth $197,000. BlueMountain Capital Management LLC purchased a new stake in shares of OraSure Technologies during the second quarter worth $209,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of OraSure Technologies during the second quarter worth $213,000. Finally, SG Americas Securities LLC raised its holdings in shares of OraSure Technologies by 155.1% during the second quarter. SG Americas Securities LLC now owns 17,091 shares of the medical instruments supplier’s stock worth $281,000 after acquiring an additional 10,390 shares in the last quarter. Institutional investors own 92.63% of the company’s stock.
Shares of NASDAQ:OSUR opened at $12.28 on Friday. OraSure Technologies, Inc. has a 1 year low of $12.22 and a 1 year high of $22.22. The firm has a market cap of $774.19 million, a P/E ratio of 24.08, a PEG ratio of 3.13 and a beta of 1.54.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, November 7th. The medical instruments supplier reported $0.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.02. The business had revenue of $45.90 million during the quarter, compared to analyst estimates of $44.50 million. OraSure Technologies had a return on equity of 6.58% and a net margin of 9.49%. OraSure Technologies’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company earned $0.09 earnings per share. As a group, analysts predict that OraSure Technologies, Inc. will post 0.32 EPS for the current year.
Several brokerages recently issued reports on OSUR. BidaskClub lowered OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday. TheStreet lowered OraSure Technologies from a “b” rating to a “c+” rating in a report on Thursday, November 8th. Zacks Investment Research lowered OraSure Technologies from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 7th. ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, November 6th. Finally, Raymond James reiterated a “mkt perform” rating on shares of OraSure Technologies in a report on Tuesday, October 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $20.50.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
See Also: Systematic Risk
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.